Home » GI Bleeding (Page 2)

Category Archives: GI Bleeding

Journal Club – September 26, 2019

Please join us for the first Journal Club Session of the year in which the following articles will be discussed:

Brendon O’Connell, MD will present the article, “Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study.”

PMID: 30635408. Gut. 2019 Aug;68(8):1379-1385. doi: 10.1136/gutjnl-2018-317513.

Surveillance interval protocols after complete remission of intestinal metaplasia (CRIM) post radiofrequency ablation (RFA) in Barrett’s esophagus (BE) are currently empiric and not based on substantial evidence. This study aimed to assess the timeline, location and patterns of recurrence following CRIM to inform these guidelines.

Farah Hussain, MD will present the article, Endoscopic scar assessment after colorectal endoscopic mucosal resection scars: when is biopsy necessary (EMR Scar Assessment Project for Endoscope (ESCAPE) trial).

PMID: 30635409. Gut. 2019 Sep;68(9):1633-1641. doi: 10.1136/gutjnl-2018-316574.

It is unclear whether endoscopic assessment of scars after colorectal endoscopic mucosal resection (EMR) has to include biopsies, even if endoscopy is negative. Vice versa, endoscopic diagnosis of recurrent adenoma may not require biopsy before endoscopic reinterventions. This study prospectively analyzed various endoscopic modalities in the diagnosis of recurrence following EMR.

Shai Posner, MD will present the article, “Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis.”

PMID: 31220444. Gastrointest Endosc 2019;90:581-90. doi: 10.1016/j.gie.2019.06.008.

TC-325 (Hemospray) is an inorganic hemostatic powder recently approved by the U.S. Food and Drug Administration. This study aimed to examine the effectiveness, safety, and predictors of TC-325 failure in a large real-life cohort.

Prior JC Conferences


July 2024